Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Prime Medicine Inc (NQ: PRME )

4.460 +0.090 (+2.06%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 832,147
Open 4.310
Bid (Size) 4.080 (10)
Ask (Size) 4.490 (6)
Prev. Close 4.370
Today's Range 4.068 - 4.480
52wk Range 3.280 - 9.860
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why I Keep Buying These 14 Incredible Growth Stocks
This diverse set of growth stocks offers tremendous opportunities in the fields of AI, space, biotech, and emerging industries. 
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Prime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson’s Disease, at Upcoming Scientific Meetings
From Prime Medicine, Inc.
Via GlobeNewswire

Performance

YTD
-49.09%
-49.09%
1 Month
+23.89%
+23.89%
3 Month
-22.97%
-22.97%
6 Month
-7.08%
-7.08%
1 Year
-36.19%
-36.19%

More News

Read More
Why Prime Medicine Stock Soared Nearly 12% Higher on Monday
Via The Motley Fool
Dow Dips 300 Points; Emcore Shares Spike Higher
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Crude Oil Moves Higher; Prime Medicine Shares Spike Higher
Via Benzinga
Exposures Fossil Fuels
Prime Medicine, MINISO Group, Li Auto, Weibo And Other Big Stocks Moving Higher On Monday
Via Benzinga
Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Prime Medicine Unveils Strategically Focused Pipeline
From Prime Medicine, Inc.
Via GlobeNewswire
Prime Medicine Announces Strategic Research Collaboration and License Agreement with Bristol Myers Squibb to Develop and Commercialize Multiple Prime Edited Ex Vivo T-Cell Therapies
From Prime Medicine, Inc.
Via GlobeNewswire
2 Growth Stocks That Could Make You Richer
Via The Motley Fool
Prime Medicine to Participate in Upcoming Investor Conferences
From Prime Medicine, Inc.
Via GlobeNewswire
PRME Stock Earnings: Prime Medicine Misses EPS for Q2 2024
Via InvestorPlace
Prime Medicine Reports Second Quarter 2024 Financial Results and Provides Business Updates
From Prime Medicine, Inc.
Via GlobeNewswire
Prime Medicine to Present at Upcoming Investor Conferences
From Prime Medicine, Inc.
Via GlobeNewswire
If You Can Only Buy One Biotech Stock in May, It Better Be One of These 3 Names
Via InvestorPlace
Exposures Product Safety
Here Are the 2 Growth Stocks Google's Parent Company Just Added to Its $7 Billion Portfolio
Via The Motley Fool
Wall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for May 2024
Via InvestorPlace
Wall Street Favorites: 3 Biotech Stocks with Strong Buy Ratings for May 2024
Via InvestorPlace
Prime Medicine to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
From Prime Medicine, Inc.
Via GlobeNewswire
PRME Stock Earnings: Prime Medicine Beats EPS for Q1 2024
Via InvestorPlace
Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates
From Prime Medicine, Inc.
Via GlobeNewswire
Prime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Granulomatous Disease (CGD)
From Prime Medicine, Inc.
Via GlobeNewswire
Why Aspen Aerogels Shares Are Trading Higher By 26%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.